Favorites Sign in

One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
  1. Home
  2. Companies
  3. FONAR Corporation
  4. Financial Statements
  5. Income Statement
FONAR Corporation logo
FONAR Corporation FONR
report update icon

Quarterly report 2026-Q3
added 05-11-2026

FONAR Corporation Income Statement 2025-2011 | FONR

Brief overview of profit and loss at FONAR Corporation

The figures are compared over a five-year interval. FONAR Corporation reported revenue of $85.7 million in 2020 and $104 million by 2025. The total change was +21.8%, with a CAGR of approximately 4%. Sales changed only slightly and remained broadly flat.

EBITDA changed from 18.6 million dollars to 4.7 million dollars (−74.7%). EBITDA lagged revenue, showing weaker operating momentum. EBITDA margin was 21.7% at the start and 4.5% at the end. A lower EBITDA share weakens the quality of the result.

Over the period, net income shifted from 8.2 million dollars to 8.3 million dollars (+1.1%). The final result remained comparatively stable.

Overall conclusion

Signs of deterioration dominate the five-year picture. The positive side is supported by a steady final result. Caution is warranted because of limited operating profitability, pressure on operating profitability and weak sales momentum. The key question is whether sales can be converted into sustainable profit.

Annual Income Statement FONAR Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

 - - - 89.5 M 91.1 M 158 M 154 M 163 M 170 M 144 M 64.3 M 68 M 35.5 M 20.3 M 10.4 M

Shares

 - - - 6.55 M 6.51 M 6.44 M 6.35 M 6.29 M 6.54 M 6.43 M 6.43 M 6.39 M 6.06 M 5.78 M 5.26 M

Historical Prices

 14.5 15.1 17 13.7 15 17.4 19.7 20.2 24.4 19.1 17.3 10.4 21.2 4.33 1.7

Net Income

 8.33 M 10.6 M 9.38 M 12.4 M 10.2 M 8.24 M 15.3 M 21.2 M 19.6 M 15.7 M 12.9 M 10.4 M 8.68 M 5.78 M 3.16 M

Revenue

 104 M 103 M 98.6 M 97.6 M 89.9 M 85.7 M 87.2 M 81.5 M 78 M 73.4 M 69.1 M 68.5 M 49.1 M 39.4 M 33.1 M

Gross Profit

 - - - - - 42.4 M 43.2 M 39.6 M 40 M 34.5 M 30.6 M 31.3 M 23 M 18.2 M 14.7 M

Operating Income

 - 4.52 M 11.1 M 5.31 M -7.09 M - - - - - - - - - -

Interest Expense

 36.2 K 78.8 K 50.1 K 347 K 249 K 74.3 K 98.6 K -160 K 28.3 K -262 K -702 K -885 K -500 K 479 K 515 K

EBITDA

 4.7 M 9.11 M 15.7 M 9.84 M -3.01 M 18.6 M 26 M 23.6 M 22.6 M 17.7 M 16.4 M 16.1 M 9.96 M 9.44 M 5.86 M

Operating Expenses

 - - - - - 28.7 M 21.1 M 19.9 M 20.9 M 20.1 M 17.7 M 19 M 15.5 M 11 M 10.9 M

General and Administrative Expenses

 29.7 M 26.9 M 29.4 M 23.5 M 24.7 M 26.7 M 19.3 M 18.1 M 19.4 M 18.5 M 13.5 M 15.4 M 12.5 M 8.75 M 8.46 M

All numbers in USD currency

Quarterly Income Statement FONAR Corporation

2026-Q3 2026-Q2 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

 6.86 M 6.86 M 6.86 M 6.86 M 6.69 M 6.86 M 7 M 6.3 M 6.44 M 7.03 M 6.44 M 6.41 M 6.53 M 6.48 M 6.53 M 6.54 M 6.53 M 6.55 M 6.55 M 6.55 M 6.55 M 6.55 M 6.46 M 6.45 M 6.46 M 6.45 M 6.45 M 6.43 M 6.45 M 6.43 M 6.36 M 6.34 M 6.36 M 6.34 M 6.29 M 6.29 M 6.29 M 6.29 M 6.16 M 6.1 M 6.16 M 6.1 M 6.05 M 6.05 M 6.05 M 6.05 M 6.05 M 6.05 M 6.05 M 6.05 M 6.01 M 5.98 M 5.99 M 5.94 M 5.93 M 5.9 M 5.93 K 5.9 K 5.73 K 5.67 K - -

Net Income

 1.64 M 2.06 M 2.06 M 2.26 M 1.96 M 2.51 M 1.96 M 3.14 M 3.76 M 1.87 M 3.76 M 4.11 M 2.23 M 3.86 M 2.23 M 2.05 M 4.28 M 2.29 M 4.02 M 3.89 M 7.91 M 3.87 M 3.11 M 2.51 M 3.11 M 2.51 M 3.1 M 3.3 M 3.1 M 3.3 M 3.55 M 3.32 M 3.55 M 3.32 M 4.19 M 3.72 M 4.19 M 3.72 M 4.24 M 3.57 M 4.24 M 3.57 M 3.49 M 2.86 M 3.49 M 2.86 M 2.66 M 2.54 M 2.66 M 2.54 M 2.14 M 2.44 M 2.14 M 2.44 M 1.35 M 1.45 M 1.35 M 1.45 M 1.54 M 1.51 M 1.54 M 1.51 M

Revenue

 26.5 M 25.5 M 25.5 M 26 M 25 M 27.2 M 25 M 25 M 25.4 M 25.7 M 25.4 M 25.8 M 24.3 M 25.4 M 24.3 M 23.2 M 47.4 M 24.6 M 24.5 M 23.7 M 48.2 M 23.1 M 21.2 M 21 M 219 K 219 K 219 K 219 K 219 K 219 K 227 K 20.7 M 227 K 21 M 20.2 M 19.3 M 39.5 M 19.3 M 18.4 M 18.7 M 18.4 M 18.7 M 18.4 M 17.6 M 18.4 M 17.6 M 17.1 M 18 M 17.1 M 18 M 17.6 M 16.8 M 17.6 M 16.8 M 9.61 M 9.51 M 9.61 M 9.51 M 9.33 M 9.61 M 9.33 M 9.61 M

Interest Expense

 4 K 3 K 3 K 3 K 1 K -1 K 1 K -1 K 10 K 45 K 10 K 48 K -208 K 15 K 12 K 14 K -197 K - 47 K 811 K 858 K 19 K 16 K 22 K 16 K 22 K 19 K 21 K -19 K -21 K -25 K -25 K -25 K -25 K -48 K -43 K -48 K -43 K -77 K -98 K -77 K -98 K -139 K -150 K 139 K 150 K 172 K 204 K 172 K 204 K 237 K 243 K 237 K 243 K 103 K 76 K 103 K 76 K 124 K 107 K 124 K 107 K

EBITDA

 - - - - 1.24 M - - - 1.22 M - - - 1.1 M - 1.1 M 1.12 M 2.22 M 1.18 M 1.19 M 1.17 M 2.36 M 1.09 M 1.04 M 968 K 1.04 M 968 K 1.01 M 995 K 1.01 M 995 K 952 K 922 K 952 K 922 K 998 K 959 K 998 K 959 K 863 K 856 K 863 K 856 K 848 K 829 K 848 K 829 K 888 K 888 K 888 K 888 K 972 K 982 K 972 K 982 K 395 K 415 K 395 K 415 K 524 K 525 K 1.05 M 525 K

General and Administrative Expenses

 8.37 M 6.24 M 6.24 M 6.81 M 6.93 M 7.99 M 6.93 M 5.13 M 5.59 M 7.59 M 5.59 M 4.87 M 6.6 M 7.14 M 6.6 M 6.33 M 12.9 M 6.07 M 4.77 M 5.09 M 9.86 M 6.11 M 4.54 M 6.16 M 4.54 M 6.16 M 4.16 M 4.29 M 4.16 M 4.29 M 3.61 M 4.26 M 3.61 M 4.26 M 3.29 M 4.08 M 3.29 M 4.08 M 4.07 M 4.06 M 4.07 M 4.06 M 3.87 M 4.19 M 4.12 M 3.78 M 3.82 M 3.58 M 3.82 M 3.58 M 4.35 M 3.74 M 4.35 M 3.74 M 2.35 M 2.21 M 2.35 M 2.21 M 2 M 2.04 M 2 M 2.04 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company FONAR Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Orthofix Medical Orthofix Medical
OFIX
 		$ 9.38 0.21 % $ 371 M curacaoCuracao
TransMedics Group TransMedics Group
TMDX
 		$ 70.78 1.32 % $ 2.41 B usaUSA
Alphatec Holdings Alphatec Holdings
ATEC
 		$ 10.46 1.37 % $ 1.57 B usaUSA
Bruker Corporation Bruker Corporation
BRKR
 		$ 54.8 1.69 % $ 8.32 B usaUSA
Abbott Laboratories Abbott Laboratories
ABT
 		$ 104.89 0.19 % $ 183 B usaUSA
Cytosorbents Corporation Cytosorbents Corporation
CTSO
 		$ 4.11 34.31 % $ 256 M usaUSA
Nevro Corp. Nevro Corp.
NVRO
 		- - $ 217 M usaUSA
Electromed Electromed
ELMD
 		$ 27.42 0.07 % $ 227 M usaUSA
Establishment Labs Holdings Establishment Labs Holdings
ESTA
 		$ 59.18 0.15 % $ 1.75 B costa-ricaCosta-rica
Venus Concept Venus Concept
VERO
 		- - $ 726 K usaUSA
Eargo Eargo
EAR
 		- - $ 10.2 M usaUSA
Sientra Sientra
SIEN
 		- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
 		- - $ 1.07 B usaUSA
Aethlon Medical Aethlon Medical
AEMD
 		$ 5.15 0.57 % $ 3.47 M usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
 		- -32.98 % $ 1.68 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
 		- - $ 12.3 B usaUSA
Abiomed Abiomed
ABMD
 		- - $ 17.2 B usaUSA
Titan Medical Titan Medical
TMDI
 		- -26.32 % $ 19.6 M canadaCanada
Natus Medical Incorporated Natus Medical Incorporated
NTUS
 		- 1.94 % $ 1.05 B usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
 		- 0.15 % $ 844 M usaUSA
Inari Medical Inari Medical
NARI
 		- - $ 4.23 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
 		- 3.58 % $ 2.21 M usaUSA
LivaNova PLC LivaNova PLC
LIVN
 		$ 77.58 0.01 % $ 4.23 B britainBritain
Avinger Avinger
AVGR
 		- -20.74 % $ 369 K usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
 		- - $ 475 M usaUSA
NuVasive NuVasive
NUVA
 		- - $ 2.07 B usaUSA
LENSAR LENSAR
LNSR
 		$ 5.8 1.0 % $ 69.4 M usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
 		- - $ 3.31 B usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
 		- -25.84 % $ 171 K usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
 		- 3.55 % $ 7.96 M usaUSA
Pulmonx Corporation Pulmonx Corporation
LUNG
 		$ 1.78 3.93 % $ 72.4 M usaUSA
Viveve Medical Viveve Medical
VIVE
 		- -15.35 % $ 1.71 M usaUSA
ViewRay ViewRay
VRAY
 		- 1.54 % $ 468 M usaUSA
SmileDirectClub SmileDirectClub
SDC
 		- -53.45 % $ 9.71 M usaUSA
Acutus Medical Acutus Medical
AFIB
 		- -26.83 % $ 2.62 M usaUSA
BIOLASE BIOLASE
BIOL
 		- -13.19 % $ 166 K usaUSA
Vapotherm Vapotherm
VAPO
 		- 6.72 % $ 34 M usaUSA
SeaSpine Holdings Corporation SeaSpine Holdings Corporation
SPNE
 		- 0.28 % $ 270 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
 		$ 0.16 3.22 % $ 19.6 M usaUSA
Zynex Zynex
ZYXI
 		- - $ 21.1 M usaUSA
Conformis Conformis
CFMS
 		- - $ 16.4 M usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
 		- 10.28 % $ 55.5 M israelIsrael
Align Technology Align Technology
ALGN
 		$ 147.31 0.83 % $ 10.7 B usaUSA
Apyx Medical Corporation Apyx Medical Corporation
APYX
 		$ 2.55 0.39 % $ 105 M usaUSA
Boston Scientific Corporation Boston Scientific Corporation
BSX
 		$ 44.39 0.53 % $ 65.7 B usaUSA
Bio-Rad Laboratories Bio-Rad Laboratories
BIO
 		$ 353.7 0.71 % $ 9.64 B usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
 		$ 9.07 4.33 % $ 257 M usaUSA
Cutera Cutera
CUTR
 		- -10.19 % $ 1.99 M usaUSA
InspireMD InspireMD
NSPR
 		$ 0.46 0.29 % $ 29.6 M israelIsrael
Butterfly Network Butterfly Network
BFLY
 		$ 7.25 3.43 % $ 1.79 B usaUSA